AzTrials
AzTrials

ExanguinationSTABLE-EMSNCT07646964

Stability of Blood Clotting Products Stored in Emergency Ambulances Under Real-World Conditions

An observational study of Exanguination and Trauma Coagulopathy, run by Medical University of Graz at 1 site in Austria.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Emergency medical service (EMS) vehicles are exposed to a wide range of environmental conditions, including high temperatures during summer months. These conditions may affect the stability and quality of medications and blood products carried for emergency treatment. Read more about this study

Who is it for?
Any age
Conditions the study is for
Exanguination, Trauma Coagulopathy
How many people
2 participants
Where
1 siteAustria
Study dates
1 Jul 2026to 30 Nov 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Child, Adult, Older adult

Study population: no study population

Who may be able to join

  • Fibryga samples stored in the participating ground-based EMS ambulance.
  • Octaplas LG AB samples stored in the participating ground-based EMS ambulance.
  • Samples available for laboratory analysis at the predefined study time points.
  • Samples exposed to routine operational storage conditions during the study period.

Who cannot join

  • Samples with damaged packaging.
  • Samples with incomplete storage documentation.
  • Samples accidentally removed from the designated storage system during the observation period.
  • Samples unavailable for laboratory analysis.
  • Samples exposed to conditions not representative of routine EMS operation.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Maximilian Niederer, MD contact

0316385081237

maximilian.niederer@medunigraz.at

Austria1 site, 1 recruiting
  • Medical University of Graz

    Graz, 8010

    Gabriel Honnef, MD, PhD, 031638581283, gabriel.honnef@medunigraz.at

    Recruiting

Other trials in Austria

About this study

Official title: Stability of Human Fibrinogen (Fibryga) and Lyophilized Human Plasma (Octaplas LG AB) Under Real-World Prehospital Emergency Medical Service Storage Conditions: A Prospective Observational Study

Emergency medical service (EMS) vehicles are exposed to a wide range of environmental conditions, including high temperatures during summer months. These conditions may affect the stability and quality of medications and blood products carried for emergency treatment.

This observational study aims to evaluate the stability of human fibrinogen concentrates and human plasma proteins (Octaplas) when stored under routine operating conditions in a ground-based EMS ambulance in Graz, Austria. Drug samples will be analyzed monthly over a four-month period and compared with reference samples stored under recommended conditions. In addition, temperature inside the storage containers and the vehicle will be continuously monitored.

The study will assess whether prolonged exposure to real-world prehospital storage conditions affects product stability and whether any changes are associated with environmental factors. The findings may help determine whether current storage practices in EMS vehicles are adequate for maintaining the quality of these blood coagulation products.

Read the detailed description

Emergency medical service (EMS) medications and blood products are routinely exposed to varying environmental conditions during storage and transport. Seasonal temperature fluctuations, prolonged vehicle operation, and environmental influences may result in deviations from manufacturer-recommended storage conditions. While several studies have demonstrated the stability of commonly used emergency medications under real-world prehospital conditions, limited evidence is available regarding the stability of blood coagulation products stored in EMS vehicles.

Human fibrinogen concentrates and lyophilized human plasma (Octaplas LG AB) are increasingly available in prehospital emergency care for the early management of severe hemorrhage and trauma. Both products are subject to specific storage requirements defined by the manufacturer. Although these products are intended to be stored under controlled conditions, maintaining recommended storage environments continuously in operational EMS vehicles may be challenging, particularly during periods of elevated ambient temperatures. Data regarding the impact of such environmental exposure on product stability in the prehospital setting remain scarce.

The objective of this prospective observational longitudinal study is to evaluate the stability of fibrinogen concentrates and Octaplas LG AB when stored under routine operating conditions in a ground-based EMS ambulance in Graz, Austria. The study will be conducted during the summer months from July through September 2026, representing the period with the highest expected thermal stress on medical products stored in emergency vehicles.

At study initiation, reference samples of both products will be retained under manufacturer-recommended storage conditions. Additional study samples will be placed in the ambulance medication storage system and exposed to routine operational conditions throughout the observation period. Laboratory analyses will be performed at predefined monthly intervals to assess potential changes in product stability over time. All analyses will be conducted at the Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, using validated laboratory methods appropriate for each product. Product-specific stability parameters will be compared with baseline and reference samples stored according to manufacturer recommendations.

Environmental conditions will be continuously monitored throughout the study period. Temperature sensors will be installed both within the medication storage containers and inside the ambulance vehicle. Measurements will be recorded automatically at 10-minute intervals over the entire observation period. These data will be used to characterize environmental exposure profiles and to quantify the frequency, magnitude, and duration of deviations from recommended storage conditions.

The primary objective is to determine whether storage under real-world prehospital operating conditions results in measurable changes in the stability of fibrinogen concentrates and Octaplas LG AB over a three-month observation period. Secondary objectives are to characterize temperature conditions within EMS medication storage systems, assess compliance with manufacturer-recommended storage conditions, quantify environmental excursions outside recommended storage ranges, evaluate potential associations between environmental exposure and laboratory measures of product stability, and describe seasonal storage conditions encountered in a ground-based EMS system.

No patients will be enrolled, and no clinical interventions will be performed as part of this study. The investigation is limited to pharmaceutical product samples and environmental monitoring within an operational EMS vehicle. Consequently, no patient-related outcomes, safety endpoints, adverse events, or clinical efficacy outcomes will be assessed.

Descriptive statistics will be used to summarize environmental and laboratory data. Continuous variables will be reported as means with standard deviations or medians with interquartile ranges, as appropriate. Longitudinal changes in laboratory stability parameters will be assessed across repeated measurements obtained during the observation period. Associations between environmental variables, including temperature and laboratory indicators of product stability will be explored using correlation analyses and regression-based approaches where appropriate. Missing measurements, if encountered, will not be imputed and will be reported transparently.

The results of this study are expected to provide evidence regarding the suitability of current EMS storage practices for blood coagulation products under routine operating conditions. The findings may contribute to future recommendations for the storage, transport, and quality assurance of coagulation products used in prehospital emergency medicine.

Keywords
Prehospital Care, Drug Storage, Temperature Monitoring, Fibrinogen Concentrate, Lyophilized Plasma, Coagulation Products

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07646964
Study groupRoleWhat they receive
Fibrinogen conentrateHuman fibrinogen concentrate samples stored under routine operating conditions in a ground-based EMS ambulance and analyzed longitudinally during the study period.
Octaplas LG ABLyophilized human plasma samples stored under routine operating conditions in a ground-based EMS ambulance and analyzed longitudinally during the study period.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Stability of fibrinogen concentrates and Octaplas LG AB During Storage Under Real-World EMS Conditions

    Change in predefined laboratory stability parameters of fibrinogen concentrates and Octaplas LG AB after storage under routine operating conditions in a ground-based emergency medical service ambulance compared with baseline reference samples stored according to manufacturer recommendations.

    Measured: Baseline to 3 months

Secondary outcomes (3)
  1. Frequency of Temperature Excursions Outside Recommended Storage Conditions

    Number and duration of temperature measurements exceeding manufacturer-recommended storage limits for Fibryga and Octaplas LG AB during the observation period.

    Measured: Continuously monitored from baseline to 3 months

  2. Maximum and Minimum Storage Temperatures

    Highest and lowest temperatures recorded within medication storage compartments and inside the ambulance vehicle during the study period.

    Measured: Baseline to 3 months

  3. Compliance With Manufacturer-Recommended Storage Conditions

    Percentage of recorded measurements within the recommended storage conditions specified by the manufacturers of Fibryga and Octaplas LG AB.

    Measured: Continuously monitored from baseline to 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jun 2026
  2. Study start1 Jul 2026
  3. Primary completion30 Sep 2026 (estimated)
  4. Study completion30 Nov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
2 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07646964
Sponsor's protocol ID
MUG-STABLEEMS-2026-01
Acronym
STABLE-EMS
Status last verified
Jun 2026
First submitted
9 Jun 2026
Last updated
8 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Pietsch U, Moeckel J, Koppenberg J, Josi D, Jungwirth A, Hautz WE, Wenzel V, Strecke S, Albrecht R. Stability of Drugs Stored in Helicopters for Use by Emergency Medical Services: A Prospective Observational Study. Ann Emerg Med. 2022 Oct;80(4):364-370. doi: 10.1016/j.annemergmed.2022.05.038. Epub 2022 Aug 1.

    PubMed 35927113
  • Helm M, Castner T, Lampl L. Environmental temperature stress on drugs in prehospital emergency medical service. Acta Anaesthesiol Scand. 2003 Apr;47(4):425-9. doi: 10.1034/j.1399-6576.2003.00062.x.

    PubMed 12694141

Questions about this trial

What is this clinical trial studying?

An observational study of Exanguination and Trauma Coagulopathy, run by Medical University of Graz at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Maximilian Niederer, MD (0316385081237, maximilian.niederer@medunigraz.at), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Stability of fibrinogen concentrates and Octaplas LG AB During Storage Under Real-World EMS Conditions (time frame: Baseline to 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07646964, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in